Experimental HIV vaccine therapy enters human testing
NCT ID NCT06430905
Summary
This early-stage study tested the safety of a new two-part vaccine therapy designed to train the immune system to recognize and fight HIV. The trial involved 30 adults with HIV who were already on stable medication that kept their virus levels very low. Participants received injections every 8 weeks for 24 weeks, followed by 6 months of monitoring to check for side effects and measure any immune response against HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconness Medical Center (BIDMC)
Boston, Massachusetts, 02215, United States
-
Brigham and Women´s Hospital
Boston, Massachusetts, 02115, United States
-
Orlando Immunology Center (OIC)
Orlando, Florida, 32803, United States
-
Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
The Hope Clinic at Emory University
Decatur, Georgia, 30030, United States
Conditions
Explore the condition pages connected to this study.